Company Encyclopedia
View More
name
Orgenesis
ORGS.US
Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration.
1.946 T
ORGS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking338/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE175.27%A
    • Profit Margin-3827.81%E
    • Gross Margin-68.59%E
  • Growth ScoreD
    • Revenue YoY-93.57%E
    • Net Profit YoY34.87%B
    • Total Assets YoY69.35%A
    • Net Assets YoY-55.66%E
  • Cash ScoreE
    • Cash Flow Margin-2.61%D
    • OCF YoY-93.57%E
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreE
    • Gearing Ratio180.60%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Orgenesis Inc. Subsidiary Theracell Secures $1 Million Convertible Loan Agreement with Alpha Prosperity Fund, Offering Up to $10 Million Credit Facility

    Orgenesis Inc.'s subsidiary, Theracell Laboratories IKE, has secured a $1 million Convertible Loan Agreement with Alpha Prosperity Fund SPC, featuring a 10% interest rate and a 36-month maturity. The agreement allows for a $10 million credit facility and includes a conversion option for the lender to acquire up to 80% equity in Orgenesis or Theracell, pending shareholder approval. Additionally, a warrant for 15% of the fully diluted share capital is included, exercisable over three years. This move aims to enhance Orgenesis's operational capabilities and growth potential.

    Reuters·
    US
    ORGS
    +341.18%
    Reuters·
    US
    ORGS
    +341.18%

    Orgenesis Inc. Announces Director Resignation as Ashish Nanda Steps Down

    Orgenesis Inc. announced the resignation of Director Ashish Nanda, effective August 21. The company clarified that his departure was not due to any disagreements regarding its operations or management.

    Reuters·
    US
    ORGS
    +341.18%
    Reuters·
    US
    ORGS
    +341.18%

    Orgenesis Inc. Announces Resignation of CFO Victor Miller and Three Directors

    Orgenesis Inc. has announced the resignation of CFO Victor Miller, effective August 8, 2025, along with directors Yaron Adler, Adam Pelavin, and Santhosh Nagaraja, whose resignations take effect on August 9 and August 18, respectively. The company stated that these departures were not due to any disagreements. This announcement highlights significant management changes within the organization.

    Reuters·
    US
    ORGS
    +341.18%
    Reuters·
    US
    ORGS
    +341.18%

    Orgenesis Inc. Downgraded to Pink Limited Tier Due to Delinquent Filing of 10-K Report

    Orgenesis Inc. has been downgraded from the OTCQX tier to the Pink Limited tier on the OTC Markets due to its failure to file the required 10-K report for the period ending December 31, 2024. The downgrade will take effect on June 3, 2025, following the company's inability to rectify this issue within the 45-day cure period provided by the OTCQX Rules.

    Reuters·
    US
    ORGS
    +341.18%
    Reuters·
    US
    ORGS
    +341.18%

    Orgenesis Inc. Delays Filing of Quarterly Report Due to Resource Allocation

    Orgenesis Inc. has delayed the filing of its Quarterly Report on Form 10-Q for the period ending March 31, 2025, due to resource allocation issues. The company is focusing on capital raising and must first file its annual report on Form 10-K for the year ending December 31, 2024. Orgenesis does not anticipate meeting the five-day extension under Rule 12b-25 and has acknowledged a potential material weakness in meeting SEC financial statement requirements on time.

    Reuters·
    US
    ORGS
    +341.18%
    Reuters·
    US
    ORGS
    +341.18%
    © 2025 Longbridge｜Disclaimer